We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Ofixu is an online platform that aim to help you with your office requirements. If you have underutilised space then Ofixu will help you earn extra cash by listing it at no extra cost. On the other hand, if you're an entrepreneur looking to rent an office, you can find one local to you by using Ofixu's worldwide search function.
days to go: Expired investment: £151,762
Love2move has developed a platform to bridge the gap between sellers/ homeowners and the market. It functions as an internet estate agent working in collaboration with well- established estate agents with a physical office. This way Love2move provides its users the best of both traditional as well as online estate agents. With the help of online sales platform, the agents can list homes without much setup costs involved.
days to go: Expired investment: £51,850
Agent House is an operational system and platform (OSP) offering business administration and marketing to independent property professionals for an affordable monthly licence fee.
days to go: Expired investment: £66,766
An online estate agent with a mission to be honest, reliable and friendly to clients who wish to sell their properties, along with offering money back guarantees. eSale is gaining popularity across England and Wales due to its strong USPs with increased instructions of 247% compared to 2017 and has recently entered the Scottish property market.
days to go: Expired investment: £3,219
A P2P property platform designed to help developers acquire credit and deliver high returns for property investors. Propifi plans to bridge the demand for finance in the UK by providing an alternative lending channel, which differs from the traditional model. Funds raised will result in parallel development of a website and smartphone app, as well as cover legal costs and allow the business to obtain FCA Registration.
days to go: Expired investment: £389,760
WeVee is a platform that brings Electric Vehicles (EVs) into one place so that potential customers can browse across different models and makes, compare them, get relevant pricing, and configure a leasing plan, with the help of reliable EV experts. The company asserts that its pricing configurator pulls from some of the UK's top lenders such as Lex Autolease, LeasePlan, Arval UK, and ALD Automotive, using Application Programming Interface (API's) to show the best price for each lease configuration. WeVee argues that over 800 vehicles have been ordered on its portal to date. It has also earned £830,000 worth of revenue since launch and garnered 350+ 5-star Trustpilot reviews. WeVee will use the investment for technology development, marketing, contingency purposes, towards paying its tech, leadership, marketing, and operations teams, and upgrades to its IT hardware.

Pitch Rated

83%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £1,602,196
Docandu is an innovative digital health platform designed both for patients & doctors, making digital healthcare accessible from anywhere. Docandu aims to be a key tech health service provider, starting from Greece, improving the existing national and private health care services. The global digital health market is estimated to be worth $536 Billion by 2025. To date, they have developed two separate apps for doctors and patients. They have also received an angel investment of 100,000 Euros and sponsorship of $25,000 from Microsoft. The company has initiated early-stage relationships with a couple of Greek public and private health entities. With the proceeds, they will execute their go-to-market strategy and make global health ID a reality, by expanding its affiliate network of doctors, health providers and public health systems.

Pitch Rated

82%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £70,900
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph